ABX-002 Enters Phase 2 With No Mechanistic Precedent and a High Payer Bar

Autobahn Initiates Phase 2 AMPLIFY Trial for MDD

Autobahn Therapeutics has initiated AMPLIFY, a Phase 2 clinical trial evaluating ABX-002 as an adjunctive treatment for adults with major depressive disorder (MDD). ABX-002 is an oral, highly potent, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance brain-specific thyroid hormone benefits. The placebo-controlled, double-blind trial will enroll 230 adults with moderate-to-severe depression, assessing safety, tolerability, efficacy, and pharmacodynamic effects when added to current SSRI/SNRI therapy. Topline data from AMPLIFY is anticipated in the second half of 2025. The company also plans to start another Phase 2 trial for ABX-002 in bipolar disorder depression by late 2024.

• The AMPLIFY trial is a pivotal Phase 2, placebo-controlled, double-blind study enrolling 230 adults suffering from moderate-to-severe major depressive disorder. Its primary objective is to evaluate the safety, tolerability, efficacy, and pharmacodynamic effects of ABX-002 when administered as an adjunctive treatment alongside patients' existing selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI) therapies. The primary endpoint focuses on the change from baseline on the Hamilton Depression Rating Scale-17 (HAMD-17) after six weeks.
• ABX-002 is characterized as a highly potent, oral, and selective thyroid hormone beta receptor (TRβ) agonist. It is specifically engineered to optimize the central nervous system (CNS) benefits of thyroid hormone biology by achieving targeted drug concentrations directly in the brain, aiming for enhanced potency and efficacy while mitigating peripheral side effects. This approach leverages the known adjunctive benefits of synthetic thyroid hormone in MDD, offering a potentially safer profile for chronic use.
• Autobahn Therapeutics projects the release of topline data from the AMPLIFY Phase 2 trial for MDD in the second half of 2025. Demonstrating a broader strategic vision for ABX-002, the company is also on track to initiate a second Phase 2 trial for the compound by the end of 2024, specifically targeting patients with bipolar disorder depression. This expansion underscores Autobahn's commitment to addressing significant unmet needs in neuropsychiatric conditions.

The Urgent Need for New Options in Major Depressive Disorder

Major depressive disorder remains a leading cause of disability worldwide, yet current treatment approaches are constrained by significant biological, clinical, and practical limitations. The classical monoamine hypothesis, which has historically guided antidepressant development, does not fully account for variability in treatment response, delayed therapeutic onset, or the persistence of cognitive and anhedonic symptoms.

• Treatment-resistant depression is prevalent and inadequately addressed. Approximately 30% of patients with MDD do not respond sufficiently to established pharmacological, psychotherapeutic, or somatic treatments. Most of these patients face a trial-and-error approach to therapeutics, which contravenes ethical criteria of patient autonomy and justice.

• Patient-prioritized outcomes are poorly captured by standard clinical measures. Survey data from 896 participants with unipolar or bipolar depression found that only 25% of the depression group reported their current treatment plan as completely effective. Outcomes patients identified as most important — such as absence of anxiety or agitation, and improved neurocognitive function — are inadequately assessed by current standard clinical trial outcome measures. Adverse effects including weight gain, lethargy, emotional blunting, shaking/trembling, and anxiety led to medication discontinuation in more than one-third of respondents.

• Biomarker-guided treatment selection remains unvalidated. A systematic review of biomarkers as predictors of tricyclic antidepressant response in MDD identified no biomarker that could be confirmed as a predictor of treatment response. Biomarker studies vary in endpoint definitions, frequently lack power calculations, and generally use small sample sizes, limiting their utility for precision treatment strategies.

• Mechanistic heterogeneity is not reflected in current diagnostic or treatment frameworks. Depressive syndromes reflect varying contributions of monoaminergic dysregulation and glutamatergic-neuroplastic impairment, yet symptom-based diagnostic systems do not capture this biological heterogeneity. Alterations in glutamatergic signaling, glial function, and BDNF-TrkB-mTOR pathways contribute to synaptic atrophy and network dysfunction that conventional monoaminergic agents do not directly target.

• Rapid-acting alternatives carry their own limitations. While ketamine demonstrates greater efficacy and a significantly faster onset of action compared to SSRIs and TCAs, its benefits are offset by a far shorter duration of antidepressant effects and accessibility limitations. Concerns also persist regarding bladder toxicity and addiction potential, and further research is needed to optimize its dosing regimen.

Unpacking the AMPLIFY Phase 2 Trial Design for ABX-002

Several randomized controlled trials have evaluated pharmacological and non-pharmacological interventions in Major Depressive Disorder (MDD), employing validated clinician-rated and self-report instruments to capture symptomatic outcomes across acute and longer-term treatment periods.

Targeting Brain Thyroid Receptors: A New Augmentation Frontier

The landscape of major depressive disorder (MDD) treatment is continually evolving, yet a significant proportion of patients still struggle with inadequate response to initial therapies, leading to what is known as treatment-resistant depression (TRD). This persistent challenge underscores the critical need for innovative and effective augmentation strategies. Autobahn Therapeutics' initiation of the AMPLIFY Phase 2 trial for ABX-002 represents a compelling step forward in this endeavor, focusing on a novel, targeted approach to an established therapeutic pathway.

ABX-002 is an oral, highly potent thyroid hormone beta receptor (TRβ) selective agonist, designed to enhance the beneficial effects of thyroid hormones specifically within the brain. This strategy is particularly intriguing given that existing literature supports the efficacy of thyroid hormone (T3) augmentation for depression, including in TRD, and suggests a favorable benefit/risk profile when combined with modern antidepressants. Moreover, research highlights the concept of 'functional hypothyroidism,' where intracellular T3 action is diminished despite normal systemic thyroid levels, often linked to elevated reverse T3 and contributing to neuropsychiatric symptoms. ABX-002's selective mechanism could directly address this imbalance, potentially offering a more precise intervention than traditional, systemic thyroid hormone administration.

The strategic implications of ABX-002 are significant. Success in the AMPLIFY trial would not only validate TRβ agonism as a targeted augmentation pathway for MDD but also pave the way for its planned expansion into bipolar disorder depression, an area with considerable unmet need where thyroid hormone augmentation has shown promise, albeit with mixed evidence in past studies. This targeted approach could differentiate ABX-002 from current augmentation options, such as second-generation antipsychotics, which are often associated with metabolic side effects, or lithium, which has its own tolerability considerations.

However, the path forward is not without its considerations. While thyroid hormone augmentation has a historical basis, demonstrating robust efficacy for ABX-002 specifically as an adjunctive treatment to contemporary SSRI/SNRI therapies in a large, randomized trial is crucial. The mixed evidence for thyroid hormone augmentation in bipolar disorder also suggests that consistent efficacy in this indication may be challenging to achieve. Furthermore, despite its selective nature, careful monitoring for any potential off-target or systemic thyroid hormone-like side effects will be essential throughout its development. If successful, ABX-002 could offer a valuable new tool for clinicians, providing a targeted, brain-specific approach to enhance antidepressant response and improve outcomes for patients struggling with severe and treatment-resistant mood disorders.